The Allergy & Asthma Network praised three major pharmaceutical companies, AstraZeneca, Boehringer Ingelheim and GSK, that announced they will enact a $35 price cap on their inhaler products ...

Eur Respir J. 2019;54 (3):1900900. Price DB, et al. Adverse outcomes from initiation of systemic corticosteroids for asthma: long-term observational study. J Asthma Allergy. 2018;11:193-204. GOLD.

AstraZeneca's drive to rebuild its portfolio of new medicines received a boost with positive results for an experimental biotech drug for severe asthma that the company previously flagged as a ...

With its latest $50 billion U.S. manufacturing investment and record U.S. growth, is British AstraZeneca looking at itself as ...

GSK, largest manufacturer of inhaler products in US, will cap out-of-pocket costs at $35 per month for its asthma, COPD inhalers by 2025. AstraZeneca, GSK, and Teva made over $25 billion in ...

Major pharmaceutical companies have agreed to cap out-of-pocket costs for some asthma patients at $35 per month, a move that offers relief but doesn't fully address the larger issue of high drug ...

Papi A, et al. Relationship of inhaled corticosteroid adherence to asthma exacerbations in patients with moderate-to-severe asthma. J Allergy Clin Immunol Pract. 2018; 6 (6): 1989-98.e3.

WILMINGTON, Del. -- (BUSINESS WIRE)-- Positive high-level results from the Phase III KALOS and LOGOS trials in patients with uncontrolled asthma showed that AstraZeneca’s fixed-dose triple ...

AstraZeneca is conducting a non-interventional, prospective study titled ‘A Non-interventional, Prospective Study With Benralizumab to Investigate Clinical Outcome Based on Standard of Care ...

LABAs, which are also used to treat the more serious lung condition chronic obstructive pulmonary disease (COPD), are blockbuster products for the companies with Advair's sales reaching about $7.8 ...

Major pharmaceutical companies have agreed to cap out-of-pocket costs for some asthma patients, but critics argue it's only part of the solution to high drug prices.